ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs.
We focus on providing products to physician specialists that support patients with serious diseases for which there is an unmet medical need, including disease caused by C1 esterase inhibitor deficiency and C. difficile.
In everything we do, throughout our organization, we are committed to patient and physician needs, as we work to bring new products to markets with few, if any, therapeutic options. We are dedicated to transforming the promise of biotechnology into therapies that have the power to restore health and save lives.
Learn about how ViroPharma is serving the unique needs of unique patient populations.
Products and Pipeline
ViroPharma’s core focus is on providing patients and physicians new therapeutic alternatives for today’s great unmet medical needs.
Our product CINRYZE® (C1 Esterase Inhibitor [Human]) is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE), a rare and potentially life threatening genetic inflammatory disorder. Our product VANCOCIN® is the only antibiotic approved to treat two significant bacterial infections of the lower digestive tract. The product is administered orally and is indicated for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by Clostridium difficile
The company is also assessing non-toxigenic C. difficile (VP20621) with the goals of preventing the recurrence of disease following effective therapy for acute C. difficile infection (CDI) and preventing CDI in patients who are susceptible to colonization with toxigenic strains due to prior use of antibiotics.
ViroPharma’s current clinical product portfolio serves as our foundation for growth, supported by revenues from product sales; and we are expanding on our franchise areas, by capitalizing on business execution and prudent business development.
ViroPharma is built on core values: customer focus, quality, passion, continuous improvement, courage, teamwork and integrity. These values are evident throughout ViroPharma: the way we conduct our business, the way we communicate with our various stakeholders, and in the manner in which we relate to one another.
At ViroPharma, we strive to improve healthcare by bringing new and important medicines to market.
Cinryze is for intravenous use only. A dose of 1000 Units Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients.
Cinryze is administered at an injection rate of 1 mL per minute
Important Information About Cinryze™
Before starting Cinryze, please read the Patient Labeling, located at www.cinryze.com/PDF/Cinryze_PI.pdf, carefully and each time you get a refill. This information does not include all of the important information about Cinryze. If you have questions after reading this, ask your healthcare provider.
Important Risk Information
You should not use Cinryze if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product.
Tell your healthcare provider about all of your medical conditions, including if you:
- Are pregnant or planning to become pregnant. It is not known if Cinryze can harm your unborn baby.
- Are breastfeeding or plan to breastfeed. It is not known if Cinryze passes into your milk and if it can harm your baby.
- Or have a history of blood clotting problems. Very high doses of C1 esterase inhibitor could increase the risk of blood clots.
Tell your healthcare provider and pharmacist about all of the medicines you take, including all prescription and non-prescription medicines such as over-the-counter medicines, supplements, or herbal remedies.
Allergic reactions may occur with Cinryze. Call your healthcare provider or get emergency support services right away if you have: wheezing, difficulty breathing, chest tightness, turning blue (look at lips and gums), fast heartbeat, swelling of the face, faintness, rash, or hives.
Because Cinryze is made from human blood, it may carry a risk of transmitting infectious agents, e.g. viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. In clinical studies, the most common side effects seen with Cinryze were upper respiratory tract infection, sinusitis, rash and headache. These are not all the possible side effects of Cinryze. Tell your healthcare provider about any side effect that bothers you or that does not go away. You can also report side effects to the FDA at 1-800-FDA-1088.
Do not use Cinryze for a condition for which it is not prescribed. Do not share Cinryze with other people, even if they have the same symptoms that you have.